AuroSource – Custom Research and Manufacturing Division of Aurobindo Pharma

By: Tarun Agarwal

A leading pharmaceutical manufacturing company, Aurobindo Pharma is headquartered at Hyderabad, India. The company which commenced operations with a single unit manufacturing Semi-Synthetic Penicillin (SSP), has now evolved into a knowledge driven company that manufacturing active pharmaceutical ingredients and formulation products.

Aurobindo Pharma is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. They are also one of the few companies to be present across the beta-lactam and non-beta-lactam segments. The company is associated with UNO for development of ARVs, and contributes to over 2300 dossier filings worldwide.

The Custom Research and Manufacturing division of Aurobindo Pharma, AuroSource offers the global bio-tech and pharmaceutical community a refreshingly new approach for outsourcing chemistry services with a dedicated focus on enhancing value with our customers. AuroSource offers project-based customer centricity in chemistry services.

Research at AuroSource is supported by a state-of-the-art R&D division located near Hyderabad. With an experience of over 200 APIs commercialization the research team is completely attuned to our business needs.

AuroSource has vast expertise in developing and manufacturing customized APIs, intermediates, starting raw materials and stability study. They also offer solutions to manage the complete product lifecycle including extensions and regulatory support.

Along with this, AuroSource also has over 1000 regulatory filings, and exports to over 125 countries. The R&D division is hugely experienced in all types of chemistry.

Manufacturing Facilities
AuroSource offers flexibility with five API development and manufacturing facilities, accredited by international regulatory bodies such as USFDA, MHRA, Health Canada, TGA, ANVISA and SA MCC.

• In stability studies, AuroSource has efficiently implemented global stability protocols for stability analysis.
• These facilities have walk in chambers for all ICH conditions with capacities of up to 100,000 litres. All stability chambers are continuously monitored.
• State-of-the-art manufacturing facilities that bolster proficiency in GMP and non-GMP processes allowing AuroSource to extend a highly competitive edge to its customers with API manufacturing needs.

Aurobindo Pharma’s manufacturing services cover the customer’s needs from R&D to plant scale material for clinical trials, and more specialized capabilities. We offer six modern scalable facilities with a total reaction volume in excess of 4500 cubic meters.

Global Expansion
AuroSource has a global presence across 100 countries including key players such as China, Brazil, Japan, Netherlands, South Africa, Thailand, UK, USA and Russia. In India, the parent company, Aurobindo Pharma has three dedicated research centres, making it one of the largest R&D facilities in the country.

Article Directory:

| More

Tarun Agarwal is a blogger with a gold medal in Chemistry. He continues to write about the latest developments in the world of medicine. He also shares his thoughts on the same by applying his knowledge in creating or modifying formulae.

Please Rate this Article


Not yet Rated

Click the XML Icon Above to Receive Industry Articles Articles Via RSS!

Powered by Article Dashboard